GSA Capital Partners’s Orphazyme A/S ORPH Stock Holding History

GSA Capital Partners’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-490,000	Closed	-$5.06M	–	1738
2020 Q3	$5.06M	Buy	+490,000	New	+$4.91M	0.84%	3

Other funds holding ORPH

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GSA Capital Partners's ORPH Position: Q4 2020 in Review

GSA Capital Partners sold out of Orphazyme A/S (ORPH) in Q4 2020, closing a stake of 490,000 shares — an estimated $5.06M sold.

GSA Capital Partners first reported a position in ORPH in Q3 2020 and held it in 1 quarter. The position peaked at $5.06M in Q3 2020. 5 funds tracked by Wall St. Rank hold ORPH as of Q4 2020.

GSA Capital Partners reported no remaining Orphazyme A/S position as of Q4 2020 after selling out during the quarter.
GSA Capital Partners sold 490,000 Orphazyme A/S shares in Q4 2020, an estimated $5.06M.
GSA Capital Partners first reported a position in Orphazyme A/S in Q3 2020 and held it in 1 quarter.
GSA Capital Partners's Orphazyme A/S position peaked at $5.06M in Q3 2020.
5 funds tracked by Wall St. Rank held Orphazyme A/S as of Q4 2020.

Based on GSA Capital Partners's 13F filing for Q4 2020, filed 3 Feb 2021.